Multi-center randomized controlled study of Chuanhuang prescription combined with reduced glutathione regimen in 2-4 CKD with 1-2 grade AKI

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2100004427

Enrollment

Unknown

Registered

2021-02-10

Start date

2021-02-22

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A on C

Interventions

Reduced glutathione group(RG group):RG group will be given RG 1.8g added to 0.9% normal saline or 5% glucose 250 ml for injection, intravenous injection (IV), once per day for 2 weeks.

Reduced glutathione combing Chuanhuangfang group(RG+CHF group):RG+CHF group will be the combination of RG group and CHF group, and intervention methods are the same with the above.

Chuanhuangfang group(CHF group):CHF group will be given CHF orally, twice per day for 2 weeks. At the same time, the concentrated solution of CHF will be given enema, once per day for 5 days, then res

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Subjects meeting the diagnostic criteria of ckd 2-4 and acute kidney injury grade 1-2; 2. Subjects who meet the diagnostic criteria of TCM syndrome of spleen kidney deficiency and toxin stasis combination; 3. 24hu Pro =2.5g; 4. Subjects aged 18-75 years old; 5. Volunteers to participate in this clinical trial and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Women who are pregnant or preparing for pregnancy and lactation; 2. Patients with serious primary diseases of other organs in urgent need of immediate treatment, or patients with consumption system diseases such as malignant tumor and active tuberculosis; 3. Patients with anorectal diseases not suitable for enema 4. Patients after renal transplantation; 5. Psychotic patients, unable to cooperate; 6. Subjects allergic to therapeutic drugs; 7. Subjects who are participating in other drug clinical trials or who have participated in other clinical trials within 3 months.

Design outcomes

Primary

Measure	Time frame
IL-18;Scr;eGFR;Neutrophil gelatinase-associated lipoprotein, NGAL;BUN;Y-GT;TNFa;IL-16;24hU-pro;	—

Countries

China

Contacts

Public ContactGong Xuezhong

Shanghai Municipal Hospital of Traditional Chinese Medicine

2071425786@qq.com+86 21 56639828

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026